Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
Conditions
Brief summary
TEAEs reported in participants receiving povorcitinib
Detailed description
For HS indication: ANdT count of 0-2 at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in F-VASI score at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in T-VASI score at each visit, For PN indication: Itch NRS score of 0 or 1 at each visit, For PN indication: IGA-CPG-S score of 0 or 1 at each visit
Interventions
DRUGPovorcitinib
Sponsors
Incyte Corp.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TEAEs reported in participants receiving povorcitinib | — |
Secondary
| Measure | Time frame |
|---|---|
| For HS indication: ANdT count of 0-2 at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in F-VASI score at each visit, For vitiligo indication: Change from baseline of the initial parent study (INCB 54707-303 or INCB 54707-304) in T-VASI score at each visit, For PN indication: Itch NRS score of 0 or 1 at each visit, For PN indication: IGA-CPG-S score of 0 or 1 at each visit | — |
Countries
Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Spain
Outcome results
None listed